Beone Medicines Ltd. (BEIGF) Stock Price & Analysis
Beone Medicines Ltd. (BEIGF) rose 0.00% to USD 21.95 as of July 25, 2026 at 06:14 UTC, according to Nexqual real-time market data.
BEIGF last closed at USD 21.95; the session ranged USD 23.75–23.75 on volume of 100 shares. Market capitalization is $29.60B, with a 52-week range of USD 15.95–25.3 (PNK). Source: Nexqual, July 25, 2026 at 06:14 UTC.
Key Statistics (as of July 25, 2026 at 06:14 UTC)
| Price | USD 21.95 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 21.95 |
| Open | USD 23.75 |
| Day Range | USD 23.75 – 23.75 |
| 52-Week Range | USD 15.95 – 25.3 |
| Volume | 100 shares |
| Market Cap | $29.60B |
| Exchange | PNK |
Technical Analysis (BEIGF)
Nexqual's technical model rates BEIGF "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of July 25, 2026 at 06:14 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 0 (oversold) |
| vs SMA50 | Below (USD 22.16) |
| MACD | -0.05 (negative) |
Analyst Ratings (BEIGF)
Wall Street analysts rate BEIGF "None", per Nexqual as of July 25, 2026 at 06:14 UTC.
| Consensus Rating | None |
|---|
Earnings (BEIGF)
| Next Earnings Date | 2026-08-05 |
|---|---|
| Revenue Estimate | $1.61B |
Source: Nexqual, July 25, 2026 at 06:14 UTC.
Financials & Fundamentals (BEIGF)
| Total Revenue | $5.74B |
|---|---|
| Revenue Growth (YoY) | +35.50% |
| Gross Margin | +88.31% |
| Operating Margin | +16.51% |
| Profit Margin | +8.94% |
| ROE | +12.42% |
| Debt / Equity | 43.13 |
| Current Ratio | 3.64 |
| Total Cash | $4.79B |
| Total Debt | $2.05B |
| Free Cash Flow | $844.56M |
Source: Nexqual, July 25, 2026 at 06:14 UTC.
Financial Health Score (BEIGF)
Nexqual rates Beone Medicines Ltd.'s overall financial health "Strong" across five dimensions, as of July 25, 2026 at 06:14 UTC.
| Growth | Strong — Revenue +40% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 88%, operating 17% |
| Balance Sheet | Strong — $4.79B cash vs $2.05B debt, net cash position |
| Cash Flow | Strong — FCF $845M, 16% margin |
| Efficiency | Mixed — ROE 12%, ROA 6.0% |
Ownership (BEIGF)
| Insider Ownership | +13.76% |
|---|---|
| Institutional Ownership | +29.08% |
| Shares Outstanding | 1.23B |
| Float | 1.02B |
Source: Nexqual, July 25, 2026 at 06:14 UTC.
Leadership (BEIGF)
Beone Medicines Ltd. is led by John V. Oyler (age 57), Co-Founder, Executive Chairman & CEO, per Nexqual as of July 25, 2026 at 06:14 UTC.
| Co-Founder, Executive Chairman & CEO | John V. Oyler (age 57) |
|---|---|
| President and Global Head of Research & Development | Wang Lai (age 48) |
| Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | Xiaodong Wang (age 62) |
| Chief Financial Officer | Aaron Rosenberg (age 48) |
| Chief Technology Officer | Marcello Damiani (age 55) |
Major Backers & Investors (BEIGF)
Notable institutional backers of Beone Medicines Ltd. include T. Rowe Price, NEW PERSPECTIVE FUND, New World Fund Inc, according to Nexqual as of July 25, 2026 at 06:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 0.4% |
| NEW PERSPECTIVE FUND | 0.2% |
| New World Fund Inc | 0.2% |
| HARTFORD MUTUAL Fd.S II INC-Hartford Schroders Emerging Markets Eqy. F | 0.15% |
| Principal Funds, Inc-Global Emerging Markets Fund | 0.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.57% |
| BlackRock | 1.02% |
Source: Nexqual, July 25, 2026 at 06:14 UTC.
From Beone Medicines Ltd.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
- The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
- The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ARGNF | ARGENX SE | USD 865 | ▲ 0% |
| BNCZF | BANCO BPM SPA | USD 17.1 | ▲ 0% |
| DNBBY | DNB ASA | USD 31.23 | ▲ 1.07% |
| BFSAF | BEFESA SA | USD 40.7 | ▲ 0% |
| APPTF | AUTOMOTIVE PPTYS REAL ESTATE IN | USD 8.67 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:14 UTC. This page is informational and not investment advice.